Secukinumab vs. Adalimumab for the Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis at 48 Weeks from a Brazilian Perspective
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.2979
https://www.valueinhealthjournal.com/article/S1098-3015(17)33313-2/fulltext
Title :
Secukinumab vs. Adalimumab for the Treatment of Psoriatic Arthritis- A Cost Per Responder Analysis at 48 Weeks from a Brazilian Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)33313-2&doi=10.1016/j.jval.2017.08.2979
First page :
A938
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
2723